Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2023-06-15 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于董事、高级管理人员增持公司股份计划进展公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress of a shareholding increase plan by a company director and senior management member. It details the number of shares purchased, dates, prices, and compliance with relevant laws. It does not contain financial statements or performance data, nor is it a report or presentation. It is a notification about a director's personal share transactions (insider trades). Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and focused solely on this topic, confirming the classification.
2023-06-15 Chinese
关于董事、高级管理人员增持公司股份计划的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding a plan by a company director and senior management (specifically a director and vice president) to increase their shareholding in the company. It details the planned share purchase, the purpose, the number of shares, the price approach, and compliance with relevant laws. There is no financial data, no report attached or referenced as published, and no mention of a meeting or voting results. This fits the definition of Director's Dealing, which covers personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on this insider share purchase plan, confirming it is not a full financial report or other category.
2023-06-12 Chinese
关于获得第一类医疗器械备案凭证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate for new products. It includes product details, regulatory approval information, and a cautionary note to investors. The document is short (796 characters) and does not contain financial data, financial results, or detailed report content. It is an official announcement about a regulatory approval event rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-05 Chinese
关于董事、高级管理人员增持公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding a company director and senior management personnel increasing their shareholding in the company. It details the number of shares purchased, dates, prices, and compliance with relevant laws and regulations. There is no financial report, earnings data, or meeting materials. This fits the definition of 'Director's Dealing' which reports personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on share transactions by a director, confirming the classification as DIRS.
2023-05-31 Chinese
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2022 annual dividend distribution by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the dividend amount, the basis for distribution, the record date, the ex-dividend date, and the method of dividend payment. It references the approval of the dividend plan at the 2022 annual general meeting and provides specific figures and dates related to the dividend payment. The document is relatively short (2606 characters) and focuses solely on the dividend distribution details without containing comprehensive financial statements or broader annual report content. Therefore, it fits the category of a Notice of Dividend Amount (DIV) rather than an Annual Report or Earnings Release.
2023-05-12 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "安徽安科生物工程(集团)股份有限公司 2023 年第一季度报告" which translates to "Anhui Anke Biotechnology (Group) Co., Ltd. 2023 First Quarter Report." It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and management discussion of financial performance for the first quarter of 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. There is no indication that this is an announcement or a certification; it is the actual report itself. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-27 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.